The Pancreas Journal of Neuroendocrine Tumors and Pancreatic Diseases and Sciences has published the North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma in the April 2021 issue. Members can access these guidelines by logging in as a member and accessing Pancreas Journal.

These guidelines represent the latest work from NANETS' Guidelines Committee, led by Lauren Fishbein, MD, PhD, MTR, Chair, Janice Pasieka, MD, Co-Chair, and Jennifer Chan, MD, MPH, Past Chair. Since 2013, NANETS has published ten guidelines.

"NANETS consensus guidelines on metastatic pheo/para were created to provide guidance in the diagnosis and treatment of these rare tumours. This comprehensive document was designed to fill in the current gaps in the field and identified areas for future clinical and translational research," said Dr. Pasieka.

"Guidelines on how to treat and monitor those with metastatic pheochromocytoma/paraganglioma were lacking. The NANETS initiative to create an expert consensus guideline on this rare disease topic serves to inform and guide physicians from multiple disciplines on the various treatment options and best practices," noted Dr. Fishbein.

Access to these and other Pancreas articles is a benefit of being a NANETS member. Visit our membership page to join today.
Authors Include: Lauren Fishbein, MD, PhD; Jaydira Del Rivero, MD; Tobias Else, MD; James R. Howe, MD; Sylvia L. Asa, MD; Debbie L. Cohen, MD; Patricia L.M. Dahia, MD, PhD; Douglas L. Fraker, MD; Karyn A. Goodman, MD; Thomas A. Hope, MD; Pamela L. Kunz, MD; Kimberly Perez, MD; Nancy D. Perrier, MD; Daniel A. Pryma, MD; Mabel Ryder, MD; Aaron R. Sasson, MD; Michael C. Soulen, M; and Camilo Jimenez, MD.

Click to access Pheo Para Guidelines.